Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to ...
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
Artificial intelligence (AI) and the Internet of Things (IoT) are about to revolutionize the biopharmaceutical industry.
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
DexCom, Inc. , the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with ...
Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) quickly reached blockbuster status within their ...
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback